# IMpower130 (NCT02367781)

> A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02367781
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Carcinoma, Non-Squamous Non-Small Cell Lung
- Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Carboplatin; Nab-Paclitaxel; Pemetrexed
- Enrollment: 723
- Primary outcome: Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population
- Primary outcome: Overall Survival (OS) in the ITT-WT Population

## Commentary we found

- Podcasts: 8
- X threads: 7
- YouTube: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=impower130-nct02367781

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02367781", "email": "<work email>"}; the inbox owner confirms by the emailed link.